Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Doxorubicin-induced death in tumour cells and cardiomyocytes: is autophagy the key to improving future clinical outcomes?

    Access Status
    Open access via publisher
    Authors
    Tacar, O.
    Dass, Crispin
    Date
    2013
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Tacar, Oktay and Dass, Crispin R. 2013. Doxorubicin-induced death in tumour cells and cardiomyocytes: is autophagy the key to improving future clinical outcomes? Journal of Pharmacy and Pharmacology. 65 (11): pp. 1577-1589.
    Source Title
    Journal of Pharmacy and Pharmacology
    DOI
    10.1111/jphp.12144
    ISSN
    0022-3573
    URI
    http://hdl.handle.net/20.500.11937/36210
    Collection
    • Curtin Research Publications
    Abstract

    Objectives: Doxorubicin, a commonly used frontline chemotherapeutic agent for cancer, is not without side-effects. The original thinking that the drug causes necrosis in tumours has largely given way to its link with apoptosis over the past two decades. Key findings: More recently, major biomarkers such as AMPK, p53 and Bcl-2 have been identified as important to apoptosis induction by doxorubicin. It is Bcl-2 and its interaction with Beclin-1 that has refocussed research attention on doxorubicin, albeit this time for its ability to induce autophagy. Autophagy can be either anticancerous or procancerous however, so it is critical that the reasons for which cancer cells undergo this type of cell biological event be clearly identified for future exploitation. Summary: Taking a step back from treating patients with large doses of doxorubicin, which causes toxicity to the heart amongst other organs, and further research with this drug's molecular signalling in not only neoplastic but normal cells, may indeed redefine the way doxorubicin is used clinically and potentially lead to better neoplastic disease management.

    Related items

    Showing items related by title, author, creator and subject.

    • Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: Comparison with osteosarcoma cells
      Tacar, O.; Indumathy, S.; Tan, M.; Baindur-Hudson, S.; Friedhuber, A.; Dass, Crispin (2015)
      Objective Doxorubicin (Dox) is a frontline chemotherapeutic against osteosarcoma (OS) that is plagued by side effects, particularly in the heart. The specific objective of this article is to investigate whether low-dose ...
    • Cardiomyocyte apoptosis vs autophagy with prolonged doxorubicin treatment: Comparison with osteosarcoma cells
      Tacar, O.; Indumathy, S.; Tan, M.; Baindur-Hudson, S.; Friedhuber, A.; Dass, Crispin (2014)
      © 2014 Royal Pharmaceutical Society. Objective: Doxorubicin (Dox) is a frontline chemotherapeutic against osteosarcoma (OS) that is plagued by side effects, particularly in the heart. The specific objective of this article ...
    • A novel Osmium-based compound targets the mitochondria and triggers ROS-dependent apoptosis in colon carcinoma
      Maillet, A.; Yadav, S.; Loo, Y.; Sachaphibulkij, K.; Pervaiz, Shazib (2013)
      Engagement of the mitochondrial-death amplification pathway is an essential component in chemotherapeutic execution of cancer cells. Therefore, identification of mitochondria-targeting agents has become an attractive ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.